Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP

References

• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74–87. doi:10.1016/j.pathol.2017.09.006
   PubMed Web of Science ®Google Scholar
• Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:262–269. doi:10.3816/CLML.2010.n.055
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190. doi:10.1200/JCO.2010.28.1618
   PubMed Web of Science ®Google Scholar
• Ng EH, Miao B, Cheung W, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994. doi:10.1056/NEJM199309303291402
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861. doi:10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842. doi:10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Han Y, Yang J, Liu P, et al. Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma. Oncologist. 2019;24:e1251–e1261. doi:10.1634/theoncologist.2018-0361
   PubMed Web of Science ®Google Scholar
• Jelicic J, Larsen TS, Frederiksen H, et al. Statistical challenges in development of prognostic models in diffuse large B-cell lymphoma: comparison between existing models - a systematic review. Clin Epidemiol. 2020;12:537–555. doi:10.2147/CLEP.S244294
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–e180. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505. doi:10.1182/asheducation-2011.1.498
   PubMed Web of Science ®Google Scholar
• Warren C, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019;10:177. doi:10.1038/s41419-019-1407-6
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109. doi:10.1038/nrc.2015.17
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322. doi:10.1056/NEJMoa1513257
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130:489–500. doi:10.1182/blood-2016-12-759621
   PubMed Web of Science ®Google Scholar
• Qualls D, Abramson JS. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2019;104:25–34. doi:10.3324/haematol.2018.195834
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology. 2001;39:156–162. doi:10.1046/j.1365-2559.2001.01196.x
   PubMed Web of Science ®Google Scholar
• Fabiani B, Delmer A, Lepage E, et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch. 2004;445:545–551. doi:10.1007/s00428-004-1129-7
   PubMed Web of Science ®Google Scholar
• Fan S, Zhao Z, Zhang Y, et al. Probability calibration-based prediction of recurrence rate in patients with diffuse large B-cell lymphoma. Biodata Min. 2021;14:38. doi:10.1186/s13040-021-00272-9
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54:961–970. doi:10.3109/0284186X.2015.1043026
   PubMed Web of Science ®Google Scholar
• Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115–124.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chen J, Cheng S, et al. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin’s lymphoma. Ebiomedicine. 2019;41:167–174. doi:10.1016/j.ebiom.2019.02.048
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55:509–514. doi:10.3109/10428194.2013.811239
   PubMed Web of Science ®Google Scholar
• Nazir A, Fawad SN, Hameed A. CNS relapse of diffuse large B cell Lymphoma A single centre experience. Pak J Med Sci. 2017;33:1454–1458. doi:10.12669/pjms.336.13812
   PubMed Web of Science ®Google Scholar
• Kang J, Chae H, Hong JY, et al. Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma. 2020;61:1119–1125. doi:10.1080/10428194.2019.1709831
   PubMed Web of Science ®Google Scholar
• Huang S, Jin L, Yang J, et al. 复发儿童B细胞淋巴瘤19例临床病理特征及治疗预后分析 [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma]. Zhonghua Er Ke Za Zhi. 2017;55:748–753. Chinese. doi:10.3760/cma.j.issn.0578-1310.2017.10.007
   PubMedGoogle Scholar